Anti CD39 antibodies and LMW inhibitors can decrease extracellular ATPase activity, increase anti-tumor inflammatory response and reduce tumor growth, as demonstrated in several animal models [34–36]. This evidence concerns the gene ENTPD1 and neoplasm.